Regulatory agencies have made recommendations on when and how to identify and characterize drug metabolites to evaluate their non-clinical toxicity. Frontage has developed an approach that integrates a series of in vitro and in vivo assays to demonstrate due diligence in meeting MIST regulatory expectations.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this webinar, Dr. Philip Tiller reviews Metabolites in Safety Testing (MIST) and discusses the scientific foundation of our analytical approach. Finally Dr. Tiller shares a case study of our success.
It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.
In this study, we quantify Neurofilament Light Chain (NF-L) in human plasma, serum, and CSF on the Quanterix Simoa™ Platform using a commercial Simoa NF-Light Assay Kit provided by Quanterix Corporation. We also discuss potential applications.